Anzeige
Mehr »
Login
Mittwoch, 02.10.2024 Börsentäglich über 12.000 News von 692 internationalen Medien
Goldpreis steigt 2024 um 30 %, aber diese Aktie legt über 333 % zu – Hier ist der Grund
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
419 Leser
Artikel bewerten:
(2)

Capita plc - Announcement of AGM Results

Capita plc - Announcement of AGM Results

PR Newswire

10 May 2022

Capita plc

Announcement of AGM Results

At the Annual General Meeting of Capita plc held on 10 May 2022 at One Silk Street, London EC2V 7NQ, all the resolutions set out in the Notice of Meeting were approved by the shareholders which were voted by way of a poll. The Board would like to thank all shareholders who participated in the AGM. The results of the poll for each resolution are provided in the table below.

Resolution 11: Re-election of Lyndsay Browne as a Director

The Board notes, and is disappointed, that Resolution 11 received less than 80% of the votes cast in favour.

The Board is proud to have been the first FTSE250 Company since the late 1980s to have appointed Employee Directors. Lyndsay has been an Employee Director since July 2019, and the Board has valued her contribution. Lyndsay is a member of the Remuneration Committee and as an Employee Director is not considered independent. However, the Board continues to believe in the importance of bringing the contributions of its Employee Directors into Committee meetings and considers that the value of the employee perspective brought by Lyndsay is of considerable value to this Committee.

However, the Board notes the concerns of certain shareholders that Lyndsay as a non-independent director is a member of the Remuneration Committee. The Board will consult with shareholders on this matter to further understand and address their concerns.

A further statement detailing the outcome of the Company's discussion with its shareholders, including any actions taken as a result, will be published by the Company by no later than 10 November 2022 in accordance with the UK Corporate Governance Code 2018.

Resolution 2: 2021 Directors' Remuneration Report

Resolution 2 to approve the Directors' Remuneration Report for the year ended 31 December 2021 was approved by c.98% of votes cast.

However, following discussions between the Chair of the Remuneration Committee and a number of Capita's major shareholders, the Board confirms that it is the Company's intention to repay the furlough related income of c.£5m received in 2021 under the Coronavirus Job Retention Scheme. The repayment will be made at the end of the Company's publicly stated disposal programme and no later than the end of H1 2023.

RESOLUTIONVOTES
FOR
%VOTES
AGAINST
%VOTES
TOTAL
% OF
ISC VOTED
VOTES
WITHHELD
1To approve the Report & Accounts for the year ended 31 December 20211,174,139,95699.98225,5650.021,174,365,52169.73%1,670,882
2To approve the Directors' Remuneration Report1,148,723,62198.0123,356,5651.991,172,080,18669.59%3,956,217
3To re-elect Jonathan Lewis as a Director1,140,623,93497.0934,233,8612.911,174,857,79569.75%1,178,613
4To elect Tim Weller as a Director1,100,753,77793.6474,709,3776.361,175,463,15469.79%573,249
5To re-elect David Lowden as a Director1,165,589,47399.219,315,9790.791,174,905,45269.76%1,130,951
6To re-elect Matthew Lester as a Director.1,174,991,85399.96476,7040.041,175,468,55769.79%567,846
7To re-elect Georgina Harvey as a Director1,169,215,68999.476,255,3480.531,175,471,03769.79%565,371
8To re-elect John Cresswell as a Director1,174,369,49699.911,107,7830.091,175,477,27969.79%559,124
9To elect Nneka Abulokwe as a Director1,141,920,59297.1433,566,1572.861,175,486,74969.79%549,659
10To re-elect Neelam Dhawan as a Director1,172,771,38599.792,455,6630.211,175,227,04869.78%809,355
11To re-elect Lyndsay Browne as a Director889,140,03975.64286,315,53024.361,175,455,56969.79%580,834
12To re-elect Joseph Murphy as a Director1,153,839,99198.1621,626,4481.841,175,466,43969.79%569,964
13To re-appoint KPMG as Auditor of the Company1,153,818,67098.1621,634,5501.841,175,453,22069.79%583,188
14To authorise the Audit & Risk Committee to fix the Auditor's remuneration.1,064,239,70790.57110,863,9949.431,175,103,70169.77%932,702
15To authorise the Directors to allot shares1,169,583,77699.505,870,0810.501,175,453,85769.79%582,546
16To authorise the Company to dis-apply statutory pre-emption rights1,141,807,29897.1433,657,0752.861,175,464,37369.79%572,030
17To approve the calling of a general meeting other than an annual general meeting on not less than 14 clear days' notice.1,170,518,86899.584,947,4590.421,175,466,32769.79%570,076
18To authorise market purchase of shares1,175,016,27999.97410,6600.031,175,426,93969.79%609,464

Please note a 'vote withheld' is not a vote under English law and is therefore not included in the calculation of votes 'for' and 'against' a resolution.

Capita plc further announces that, in accordance with the provisions of paragraph 9.6.2 of the Listing Rules, copies of resolutions other than those concerning ordinary business passed at the Annual General Meeting, have been submitted to the National Storage Mechanism, and can be viewed at https://data.fca.org.uk/#/nsm/nationalstoragemechanism

Enquiries:Claire Denton, Chief General Counsel and Company Secretary, Telephone number: +44 (0) 20 7799 1525

© 2022 PR Newswire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.